The Experts below are selected from a list of 1173 Experts worldwide ranked by ideXlab platform

Yanping Ding - One of the best experts on this subject based on the ideXlab platform.

  • reshaping prostate tumor microenvironment to suppress Metastasis via cancer associated fibroblast inactivation with peptide assembly based nanosystem
    ACS Nano, 2019
    Co-Authors: Yanping Ding, Jiayan Lang, Xiao Zhao, Yinlong Zhang, Xuexiang Han
    Abstract:

    Prostate cancer is one of the most common malignant tumors in men, and inhibiting Metastasis is a key event but still a major challenge in prostate cancer treatment. Cancer-associated fibroblasts (CAFs) play an important role in prostate tumor Metastasis by shaping the malignant tumor microenvironment. Herein, we constructed a CAF-targeting siRNA delivery system by loading the fibroblast activation protein-α (FAP-α) antibody onto the cell-penetrating peptide (CPP)-based nanoparticles, which specifically downregulated C-X-C motif chemokine ligand 12 (CXCL12) expression in CAFs. This regulation generated a series of changes through inactivating CAFs so that the malignant prostate tumor microenvironment was reshaped. The tumor cell invasion, migration, and tumor angiogenesis were significantly inhibited, which all contributed to the suppression of the Metastasis of an orthotopic prostate tumor. This tumor microenvironment reshaping strategy via CAF targeting and inactivation provides an alternative approach for malignant prostate tumor Metastasis Inhibition.

  • Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours
    Nature biomedical engineering, 2017
    Co-Authors: Yinlong Zhang, Yanping Ding, Xiao Zhao, Jing Wang, Ying Zhao, Xiaozheng Zhao, Ruifang Zhao
    Abstract:

    Limited intratumoural perfusion and nanoparticle retention remain major bottlenecks for the delivery of nanoparticle therapeutics into tumours. Here, we show that polymer-lipid-peptide nanoparticles delivering the antiplatelet antibody R300 and the chemotherapeutic agent doxorubicin can locally deplete tumour-associated platelets, thereby enhancing vascular permeability and augmenting the accumulation of the nanoparticles in tumours. R300 is specifically released in the tumour on cleavage of the lipid-peptide shell of the nanoparticles by matrix metalloprotease 2, which is commonly overexpressed in tumour vascular endothelia and stroma, thus facilitating vascular breaches that enhance tumour permeability. We also show that this strategy leads to substantial tumour regression and Metastasis Inhibition in mice.

Yinlong Zhang - One of the best experts on this subject based on the ideXlab platform.

  • reshaping prostate tumor microenvironment to suppress Metastasis via cancer associated fibroblast inactivation with peptide assembly based nanosystem
    ACS Nano, 2019
    Co-Authors: Yanping Ding, Jiayan Lang, Xiao Zhao, Yinlong Zhang, Xuexiang Han
    Abstract:

    Prostate cancer is one of the most common malignant tumors in men, and inhibiting Metastasis is a key event but still a major challenge in prostate cancer treatment. Cancer-associated fibroblasts (CAFs) play an important role in prostate tumor Metastasis by shaping the malignant tumor microenvironment. Herein, we constructed a CAF-targeting siRNA delivery system by loading the fibroblast activation protein-α (FAP-α) antibody onto the cell-penetrating peptide (CPP)-based nanoparticles, which specifically downregulated C-X-C motif chemokine ligand 12 (CXCL12) expression in CAFs. This regulation generated a series of changes through inactivating CAFs so that the malignant prostate tumor microenvironment was reshaped. The tumor cell invasion, migration, and tumor angiogenesis were significantly inhibited, which all contributed to the suppression of the Metastasis of an orthotopic prostate tumor. This tumor microenvironment reshaping strategy via CAF targeting and inactivation provides an alternative approach for malignant prostate tumor Metastasis Inhibition.

  • Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours
    Nature biomedical engineering, 2017
    Co-Authors: Yinlong Zhang, Yanping Ding, Xiao Zhao, Jing Wang, Ying Zhao, Xiaozheng Zhao, Ruifang Zhao
    Abstract:

    Limited intratumoural perfusion and nanoparticle retention remain major bottlenecks for the delivery of nanoparticle therapeutics into tumours. Here, we show that polymer-lipid-peptide nanoparticles delivering the antiplatelet antibody R300 and the chemotherapeutic agent doxorubicin can locally deplete tumour-associated platelets, thereby enhancing vascular permeability and augmenting the accumulation of the nanoparticles in tumours. R300 is specifically released in the tumour on cleavage of the lipid-peptide shell of the nanoparticles by matrix metalloprotease 2, which is commonly overexpressed in tumour vascular endothelia and stroma, thus facilitating vascular breaches that enhance tumour permeability. We also show that this strategy leads to substantial tumour regression and Metastasis Inhibition in mice.

Jiayan Lang - One of the best experts on this subject based on the ideXlab platform.

  • reshaping prostate tumor microenvironment to suppress Metastasis via cancer associated fibroblast inactivation with peptide assembly based nanosystem
    ACS Nano, 2019
    Co-Authors: Yanping Ding, Jiayan Lang, Xiao Zhao, Yinlong Zhang, Xuexiang Han
    Abstract:

    Prostate cancer is one of the most common malignant tumors in men, and inhibiting Metastasis is a key event but still a major challenge in prostate cancer treatment. Cancer-associated fibroblasts (CAFs) play an important role in prostate tumor Metastasis by shaping the malignant tumor microenvironment. Herein, we constructed a CAF-targeting siRNA delivery system by loading the fibroblast activation protein-α (FAP-α) antibody onto the cell-penetrating peptide (CPP)-based nanoparticles, which specifically downregulated C-X-C motif chemokine ligand 12 (CXCL12) expression in CAFs. This regulation generated a series of changes through inactivating CAFs so that the malignant prostate tumor microenvironment was reshaped. The tumor cell invasion, migration, and tumor angiogenesis were significantly inhibited, which all contributed to the suppression of the Metastasis of an orthotopic prostate tumor. This tumor microenvironment reshaping strategy via CAF targeting and inactivation provides an alternative approach for malignant prostate tumor Metastasis Inhibition.

Xiao Zhao - One of the best experts on this subject based on the ideXlab platform.

  • reshaping prostate tumor microenvironment to suppress Metastasis via cancer associated fibroblast inactivation with peptide assembly based nanosystem
    ACS Nano, 2019
    Co-Authors: Yanping Ding, Jiayan Lang, Xiao Zhao, Yinlong Zhang, Xuexiang Han
    Abstract:

    Prostate cancer is one of the most common malignant tumors in men, and inhibiting Metastasis is a key event but still a major challenge in prostate cancer treatment. Cancer-associated fibroblasts (CAFs) play an important role in prostate tumor Metastasis by shaping the malignant tumor microenvironment. Herein, we constructed a CAF-targeting siRNA delivery system by loading the fibroblast activation protein-α (FAP-α) antibody onto the cell-penetrating peptide (CPP)-based nanoparticles, which specifically downregulated C-X-C motif chemokine ligand 12 (CXCL12) expression in CAFs. This regulation generated a series of changes through inactivating CAFs so that the malignant prostate tumor microenvironment was reshaped. The tumor cell invasion, migration, and tumor angiogenesis were significantly inhibited, which all contributed to the suppression of the Metastasis of an orthotopic prostate tumor. This tumor microenvironment reshaping strategy via CAF targeting and inactivation provides an alternative approach for malignant prostate tumor Metastasis Inhibition.

  • Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours
    Nature biomedical engineering, 2017
    Co-Authors: Yinlong Zhang, Yanping Ding, Xiao Zhao, Jing Wang, Ying Zhao, Xiaozheng Zhao, Ruifang Zhao
    Abstract:

    Limited intratumoural perfusion and nanoparticle retention remain major bottlenecks for the delivery of nanoparticle therapeutics into tumours. Here, we show that polymer-lipid-peptide nanoparticles delivering the antiplatelet antibody R300 and the chemotherapeutic agent doxorubicin can locally deplete tumour-associated platelets, thereby enhancing vascular permeability and augmenting the accumulation of the nanoparticles in tumours. R300 is specifically released in the tumour on cleavage of the lipid-peptide shell of the nanoparticles by matrix metalloprotease 2, which is commonly overexpressed in tumour vascular endothelia and stroma, thus facilitating vascular breaches that enhance tumour permeability. We also show that this strategy leads to substantial tumour regression and Metastasis Inhibition in mice.

Anne Close - One of the best experts on this subject based on the ideXlab platform.

  • Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Future medicinal chemistry, 2016
    Co-Authors: Anne Close
    Abstract:

    Angiogenesis is a process essential for tumor growth and Metastasis. Inhibition of angiogenesis as an anticancer strategy has shown only moderately improved results and is beset with practical limitations, despite theoretical therapeutic advantages. Inevitably resistance develops, through redundancy of signaling pathways and selection for subclonal populations adapted for hypoxic conditions, with more invasive phenotypes. Antiangiogenic-targeted therapies may find improved efficacy in combination therapies; with others in this class, that directly or indirectly target separate pathways or different components of the same pathway, or with a separate class of tumor vasculature-disrupting agents. This review discusses the challenges and strategies for optimization of combination therapies including metronomic administration of drugs and the need for suitable prognostic and surrogate response biomarkers.